{"id":"NCT02721641","sponsor":"Hoffmann-La Roche","briefTitle":"A Continuation Study of Herceptin (Trastuzumab) in Participants With Metastatic or Locally Advanced Cancer","officialTitle":"A Single Arm, Multi-Center, International, Continuation Trial of Recombinant Humanized Antibody Herceptin (Trastuzumab) in Patients With HER2-Overexpressing Tumors","status":"COMPLETED","phase":"PHASE3","dates":{"start":"1999-06","primaryCompletion":"2015-02","completion":"2015-02","firstPosted":"2016-03-29","resultsPosted":"2017-03-31","lastUpdate":"2017-03-31"},"enrollment":69,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Neoplasms"],"interventions":[{"type":"DRUG","name":"Herceptin","otherNames":["Trastuzumab"]}],"arms":[{"label":"Herceptin","type":"EXPERIMENTAL"}],"summary":"This study is designed to provide continued access to intravenous (IV) Herceptin and to evaluate long-term outcomes and overall safety in participants with stable disease and human epidermal growth factor 2 (HER2)-overexpressing metastatic or locally advanced cancer who have completed a prior study with IV Herceptin.","primaryOutcome":{"measure":"On-Study Duration of Trial Treatment","timeFrame":"From date of enrollment until death or premature withdrawal (maximum 7.4 years of follow-up)","effectByArm":[{"arm":"Herceptin","deltaMin":386,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":4},"locations":{"siteCount":41,"countries":["Australia","Belgium","China","France","Germany","Guatemala","Hungary","Israel","New Zealand","Panama","Poland","Portugal","Russia","Serbia","South Korea","Spain","United Kingdom"]},"refs":{"pmids":["29544445"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":11,"n":69},"commonTop":[]}}